Evidence map›Paper›PMID 36536432›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2022

Evaluation of integrin α

Yiqian Liang, Xi Jia, Yuanbo Wang, Yan Liu, Xiaobao Yao, Yanxia Bai, Peng Han, Si Chen, Aimin Yang, Rui Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. EGFR- and Integrin αInternational journal of molecular sciences · 2024
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yiqian LiangDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xi JiaDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yuanbo WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yan LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiaobao YaoDepartment of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yanxia BaiDepartment of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Peng HanDepartment of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Si ChenFoshan Atomical Medical Equipment Ltd, Foshan, China.
Aimin YangDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Rui GaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. jacky_mg@xjtufh.edu.cn.ORCID http://orcid.org/0000-0003-4841-5929
First Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

National Natural Science Foundation of China 81902322Natural Science Basic Research Program of Shaanxi Province 2020JQ-526
6 · The paper itself

Abstract

backgroundHigh-risk differentiated thyroid cancer (DTC) needs effective early prediction tools to improving clinical management and prognosis. This cohort study aimed to investigate the prognostic impact of

methodsThirty-three patients with high-risk DTC were prospectively recruited; all patients underwent total thyroidectomy and received

results

conclusions

Indexed as

AdenocarcinomaThyroid NeoplasmsCohort StudiesDisease ProgressionHumansIntegrin alphaVbeta3Iodine RadioisotopesIntegrin alphaVbeta3Iodine-131Iodine Radioisotopes99mTc-3PRGD2Differentiated thyroid cancerDisease progressionIntegrin αvβ3SPECT/CT

Identifiers

PMID36536432
PMCPMC9764676
OpenAlexW4312095159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.